GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OSTO:SOBI) » Definitions » Shiller PE Ratio

Swedish Orphan Biovitrum AB (OSTO:SOBI) Shiller PE Ratio : 34.54 (As of May. 05, 2025)


View and export this data going back to 2006. Start your Free Trial

What is Swedish Orphan Biovitrum AB Shiller PE Ratio?

As of today (2025-05-05), Swedish Orphan Biovitrum AB's current share price is kr299.80. Swedish Orphan Biovitrum AB's E10 for the quarter that ended in Mar. 2025 was kr8.68. Swedish Orphan Biovitrum AB's Shiller PE Ratio for today is 34.54.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Shiller PE Ratio or its related term are showing as below:

OSTO:SOBI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 28.96   Med: 45.62   Max: 545.59
Current: 34.54

During the past years, Swedish Orphan Biovitrum AB's highest Shiller PE Ratio was 545.59. The lowest was 28.96. And the median was 45.62.

OSTO:SOBI's Shiller PE Ratio is ranked worse than
69.77% of 526 companies
in the Drug Manufacturers industry
Industry Median: 24.365 vs OSTO:SOBI: 34.54

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Swedish Orphan Biovitrum AB's adjusted earnings per share data for the three months ended in Mar. 2025 was kr2.520. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is kr8.68 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Swedish Orphan Biovitrum AB Shiller PE Ratio Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Shiller PE Ratio Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.07 38.36 33.79 37.27 37.46

Swedish Orphan Biovitrum AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.31 37.08 40.77 37.46 33.11

Competitive Comparison of Swedish Orphan Biovitrum AB's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Shiller PE Ratio falls into.


;
;

Swedish Orphan Biovitrum AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Swedish Orphan Biovitrum AB's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=299.80/8.68
=34.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, Swedish Orphan Biovitrum AB's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=2.52/132.8245*132.8245
=2.520

Current CPI (Mar. 2025) = 132.8245.

Swedish Orphan Biovitrum AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201506 -0.010 99.995 -0.013
201509 0.019 100.228 0.025
201512 -0.048 100.276 -0.064
201603 1.070 100.751 1.411
201606 1.098 101.019 1.444
201609 0.478 101.138 0.628
201612 0.267 102.022 0.348
201703 0.716 102.022 0.932
201706 0.936 102.752 1.210
201709 1.146 103.279 1.474
201712 1.261 103.793 1.614
201803 1.815 103.962 2.319
201806 2.417 104.875 3.061
201809 2.197 105.679 2.761
201812 2.092 105.912 2.624
201903 2.980 105.886 3.738
201906 1.614 106.742 2.008
201909 1.748 107.214 2.166
201912 4.394 107.766 5.416
202003 3.802 106.563 4.739
202006 0.907 107.498 1.121
202009 0.888 107.635 1.096
202012 4.805 108.296 5.893
202103 2.226 108.360 2.729
202106 0.860 108.928 1.049
202109 1.519 110.338 1.829
202112 3.993 112.486 4.715
202203 1.748 114.825 2.022
202206 0.821 118.384 0.921
202209 1.420 122.296 1.542
202212 4.450 126.365 4.677
202303 3.400 127.042 3.555
202306 0.710 129.407 0.729
202309 0.300 130.224 0.306
202312 2.990 131.912 3.011
202403 2.330 132.205 2.341
202406 0.650 132.716 0.651
202409 4.220 132.304 4.237
202412 4.020 132.987 4.015
202503 2.520 132.825 2.520

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Swedish Orphan Biovitrum AB  (OSTO:SOBI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Swedish Orphan Biovitrum AB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB Business Description

Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB Headlines

No Headlines